Latest Biotechnology Sector Performance News

Page 1 of 1

CSL Delivers 6% Profit Growth, Reaffirms Strong FY25 Outlook Amid Seqirus Challenges

CSL Limited reported a solid 5% revenue increase and 6% rise in net profit after tax for the half year ended December 2024, underpinned by robust performance in its plasma therapies business despite headwinds in its influenza vaccine segment.

Victor Sage

11 Feb 2025

Browse the archive

Full archive

Aug 2026 July 2026 June 2026 May 2026 Apr 2026 Mar 2026 Feb 2026 Jan 2026